Novartis enhances its focus with eyecare deal


Swiss pharma major Novartis is continuing its quest to excel in a few specialist fields by licensing rights to US firm Ophthotech’s lead candidate, Fovista, for wet age-related macular degeneration (AMD). Novartis will pay $200 million (£118 million) up front, with potential regulatory and sales milestone payments adding up to over $1 billion.

Novartis will market the DNA aptamer-based drug outside of the US, and will investigate combination therapies with complementary AMD drugs it has in development. Fovista is a short length of DNA designed to bind to and inactivate platelet-derived growth factor (PDGF). It has performed well in clinical trials in combination with antibody drug Lucentis (ranibizumab), which is marketed by Novartis and binds to vascular endothelial growth factor. Blocking the action of these two growth factor proteins stops blood vessels from growing into the retina, which is the main cause of wet AMD.


Related Content

$25bn-plus trade sharpens pharma giants’ focus

25 April 2014 Business

news image

Novartis’ asset swaps with GSK and Eli Lilly are the latest steps in an ongoing streamlining process

Business roundup

28 January 2010 Business

news image

Industry news, February 2010

Most Read

Linguistic statistics enable synthetic prophetics

17 July 2014 Research

news image

A metric more commonly used by search engines to analyse language can now power organic chemistry retrosyntheses

Coffee cup confusion

20 July 2014 Research

news image

Scientists call for better labelling after research highlights inconsistencies in the chemical composition of a cup of coffee

Most Commented

Royal Society of Chemistry's flagship journal now free to access

16 July 2014 News and Analysis

news image

Chemical Science will follow gold open access model from January 2015 and waive author fees for two years

Coffee cup confusion

20 July 2014 Research

news image

Scientists call for better labelling after research highlights inconsistencies in the chemical composition of a cup of coffee